CAPRELSA vandetanib

Drug Class

Kinase inhibitor (VEGFR, EGFR, and RET)

Mechanism

Inhibits VEGFR, EGFR, and RET tyrosine kinases to block angiogenesis, tumor growth, and metastatic dissemination.

Approved Indication

FDA-approved for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.

What This Means For Patients

CAPRELSA is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2011) — Sources
• EMA — Approved (2012) — Sources

Pivotal Clinical Evidence

• ZETA — Wells et al., J Clin Oncol 2012 (NCT00410761) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa